[131I]间碘苄胍治疗恶性副神经节瘤
[131I]metaiodobenzylguanidine treatment of a malignant paraganglioma.
作者信息
Baulieu J L, Guilloteau D, Calais G, Lefloch O, Besnard J C
机构信息
Service de Médecine Nucléaire, Hôpital Bretonneau, Tours, France.
出版信息
J Nucl Biol Med (1991). 1991 Oct-Dec;35(4):313-4.
The bone metastases of a malignant, non-secreting paraganglioma were treated with [131I]metaiodobenzylguanidine (131I-MIBG) over a 10-year period. Initial treatment (131I-MIBG: 9.6 GBq) resulted in a decrease in the number of bone metastases from 16 to 2. At three years, a relapse with primary tumor regrowth and liver metastasis was again treated with 131I-MIBG (22.2 GBq). A decrease in the number of bone metastases and MIBG uptake was again observed.
在10年期间，采用[131I]间碘苄胍（131I-MIBG）治疗了1例恶性、无分泌功能的副神经节瘤骨转移患者。初始治疗（131I-MIBG：9.6 GBq）使骨转移灶数量从16个减少至2个。3年后，患者出现原发性肿瘤复发和肝转移，再次接受131I-MIBG治疗（22.2 GBq）。骨转移灶数量和MIBG摄取量再次减少。
Zotero 插件